Anti-alpha-synuclein Antibody for Aggregate Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for alpha-synucleinopathies, such as Parkinson's disease, have low target specificity and short half-life, requiring high doses and failing to effectively bind to alpha-synuclein aggregates, which are toxic and contribute to neurodegeneration.
Innovation Solution
Development of an antibody or antigen-binding fragment that specifically binds to alpha-synuclein aggregates, particularly amyloid fibrils and oligomers, with high affinity, reducing their levels and inhibiting cell-to-cell transmission, while promoting phagocytic uptake, thereby addressing the toxicity and accumulation of alpha-synuclein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If low molecular weight compounds are used as therapeutic agents, then they can be administered, but they require high doses due to low target specific binding capacity and short half-life
Solution Approach 1:
The patent changes the molecular size parameter from low molecular weight compounds to high molecular weight antibodies (IgG1 isotype), which fundamentally alters the binding capacity and half-life characteristics, eliminating the need for high doses while improving target specificity
Solution Approach 2:
The patent uses composite antibody structures (IgG1 isotype with specific heavy chain and light chain sequences) that combine high affinity binding sites with extended half-life properties, creating a therapeutic agent that simultaneously achieves high target specific binding capacity and prolonged duration of action
2Duration of action of stationary object
If conventional therapeutic agents are used, then they can be administered, but they have short half-life and fail to effectively bind to alpha-synuclein aggregates
Solution Approach 1:
The patent changes the molecular weight and structural parameters of the therapeutic agent from low molecular weight compounds to high molecular weight antibodies, which inherently provides longer half-life while the specific antigen-binding sites are optimized for high affinity binding to alpha-synuclein aggregates
Solution Approach 2:
The patent creates a synthetic antibody molecule that copies and enhances the natural immune response mechanism, using recombinant DNA technology to produce an IgG1 antibody that mimics and amplifies the body's natural ability to recognize and bind to pathological aggregates with high affinity and long duration
3Reliability
If antibodies with high affinity for aggregates are developed, then target specificity is improved, but the complexity of development increases
Solution Approach 1:
The patent segments the antibody molecule into distinct functional components (heavy chain with specific CDR sequences for aggregate recognition, light chain for affinity enhancement, Fc region for half-life extension), allowing each segment to be independently optimized and simplifying the development process through modular design
Solution Approach 2:
The patent designs a universal antibody platform (IgG1 isotype with conserved framework regions) that can bind to multiple conformational states of alpha-synuclein aggregates (monomers, oligomers, fibrils) while maintaining high affinity, making the therapeutic agent effective across different stages of aggregate formation without requiring multiple specialized antibodies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively reduces alpha-synuclein aggregate levels, inhibits their transmission, and enhances phagocytic uptake, providing a more targeted and sustained therapeutic approach for alpha-synucleinopathies, potentially improving symptoms and slowing disease progression.
Implementation Method 1
The antibody or an antigen-binding fragment thereof being capable of specifically binding to alpha-synuclein, especially alpha-synuclein aggregate
Implementation Method 2
improvement of phagocytic uptake of a nerve cell for alpha-synuclein or alpha-synuclein aggregate
Data Source
AI summary
The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.